---
title: "irbesartan - Diabetic Nephropathies"
sidebar: mydoc_sidebar
permalink: irbesartandiabeticnephropathies.html
toc: false 
---

{% include image.html url="images/irbesartandiabeticnephropathies.png" file="irbesartandiabeticnephropathies.png" alt="irbesartandiabeticnephropathies" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C081309 | Irbesartan | Drug |
| UniProt:P30556 | Type-1 angiotensin II receptor | Protein |
| MESH:D000804 | Angiotensin II | ChemicalSubstance |
| MESH:D014661 | Vasoconstriction | Disease |
| GO:0045777 | Up regulation of blood pressure | BiologicalProcess |
| MESH:D003928 | Diabetic Nephropathies | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Irbesartan | DECREASES ACTIVITY OF | Type-1 Angiotensin Ii Receptor |
| Type-1 Angiotensin Ii Receptor | POSITIVELY CORRELATED WITH | Angiotensin Ii |
| Angiotensin Ii | CAUSES | Vasoconstriction |
| Vasoconstriction | CONTRIBUTES TO | Up Regulation Of Blood Pressure |
| Up Regulation Of Blood Pressure | AFFECTS RISK FOR | Diabetic Nephropathies |
|---------|-----------|---------|

Reference: [https://go.drugbank.com/drugs/DB01029#mechanism-of-action](https://go.drugbank.com/drugs/DB01029#mechanism-of-action){:target="_blank"}